



Our mission is to create the leading NASDAQ small-cap international cannabis company

NASDAQ: FLGC

September 2024

General

The information contained herein, and any other materials provided by Flora Growth Corp. ("Flora" or the "Company"), are intended solely for discussion purposes and are not intended as, and do not constitute, an offer to sell or a solicitation of an offer to buy any security, and should not be relied upon by you in evaluating the merits of investing in any securities. This investor presentation is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use is contrary to local law or regulation.

This presentation contains information pertaining to the business, operations and assets of Flora. The information contained in this presentation is provided as at the date hereof and is subject to change without notice.

The Company believes the information contained in this presentation to be reliable but makes no warranty or representation, whether express or implied, in respect of, and assumes no legal liability for, the accuracy, completeness or usefulness of any information disclosed. Any estimates, investment strategies, and views expressed in this presentation are based upon current market conditions, and/or data and information provided by unaffiliated third parties, and are subject to change without notice.

No person is authorized to copy or re-distribute any materials in this presentation without the express permission of Flora.

All currency values are denominated in United States dollars unless otherwise specified.

Market and Industry Data

This presentation includes market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this presentation, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.

Cautionary Statement Concerning Forward-Looking Statements.

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the "U.S. Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. These statements include, but are not limited to, the reasons to invest in cannabis today, including any and all management estimates about future performance in the next cycle; the support of any U.S. presidential candidates or other politicians in the U.S. for any cannabis reform; the size of the U.S. cannabis industry; the U.S. cannabis industry's impact on the economy; the relative daily cannabis use compared to daily alcohol use; the future demand for cannabinoids; the total economic impact of cannabinoids on the U.S. economy; the ability for Flora to be well positioned to enter THC market when regulations permit, if at all; the general economic environment creating an opportunity for retail investors; the size of the German cannabis market; the size of the European Union cannabis market; the ability for Germany to remain one of the leaders in the European medical cannabis industry; the ability for Flora to be strategically positioned to benefit from global cannabis developments in Germany, United Kingdom and the rest of the European Union; the ability to obtain share price targets; the relative value Flora and the cannabis industry compared to alcohol, tobacco and CPG industries; the growth prospects of the cannabis industry; the ability for Flora to execute its strategic growth plan as one of the leaders in the global market for cannabis and its derivatives. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this presentation and other statements made from time to time by us or our representatives may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Such forward-looking statements are subject to various risks and uncertainties, including those described under section entitled "Risk Factors" in Flora's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the "SEC") on March 28, 2024, as such factors may be updated from time to time in Flora's periodic filings with the SEC, which are accessible on the SEC's website at www.sec.gov/edgar. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, or the forward-looking events discussed in this presentation and other statements made from time to time by us or our representatives not occurring, except as may be required by applicable law.

United Securities Laws

This presentation is not a prospectus or an offering memorandum pursuant to applicable U.S. securities laws. The securities of Flora may not be offered or sold in the United States unless pursuant to the registration requirements of the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements.


- A serial entrepreneur, financier and business executive
- **Chairman and CEO** of Flora Growth Corp. (NASDAQ: FLGC), a global player in consumer products and cannabis
- Arranged **over \$1 billion** in equity and debt financing, raised over **\$200 million** in the cannabis sector and has been in multiple successful exits
- Has been focused exclusively on the cannabis space since 2013, playing a pivotal role in the industry's evolution
- Chairman of the **U.S. Hemp Roundtable**


Ventures and Exits



Why invest in cannabis today?

Amplify Alternative Harvest ETF (MJ)










- **A record 70%** of Americans support legalizing cannabis according to Gallup.
- **79% of Americans** live in an area with at least one dispensary.
- **Half of Americans** have tried cannabis.
- The U.S. cannabis industry is expected to reach almost **\$40 billion** in 2024 according to Grand View Research.
- Cannabis will add **\$115.2 billion** to the economy in 2024.
- **47 states** have instituted some form of cannabis legalization.
- Adult-use cannabis is now **legal in 24 states**. Medical cannabis is legal in **38 states** for medical use.
- **Current opportunity for investors:**
 - US multi-state operators unable to merge due to state specific regulations
 - Institutional investors restricted from buying cannabis stocks

Despite the industry achieving **strong revenues**, valuations have declined and become **more attractive** CAGR of 12.1% through 2030 towards being a \$76.4 billion market(1) vs. Alcohol being \$260 billion.



According to Carnegie Mellon University, daily cannabis use is more common than alcohol consumption, with roughly **17.7 million users** compared to 14.7 million for alcohol.

(1) U.S. Cannabis Market Size & Share | Industry Report, 2030 (grandviewresearch.com)



One of the first U.S. exchange listings for a cannabis company

Raised an aggregate of \$135 million since inception

Maintains a clean balance sheet with no long-term debt, \$6.1 million cash, and \$2.0 million available on lines of credit

Earned \$76.1 million in revenue in 2023 with YOY Growth – 128%; Reduced cash used in operations by 91% in Q2 2024

Over 400 products across 15 unique categories

Active in 28 countries with 20,000+ distribution points

Employs 108 professionals across the globe

13.3 million shares outstanding and 10% insider ownership

Secured the first cannabis license and gram sold and obtained first cultivation license in Germany.

One of the best selling CBD gummies in the world

Buy recommendation and \$6 share price issued by Roth MKM

Focused on acquiring cashflow positive and strategic businesses

Canada
Corporate Head Office

Domiciled and incorporated in Toronto, Ontario.

United Kingdom
Satellite Office

Sales and distribution centre for Europe.

Denmark

Europe's first legal genetics and seedbank.

Germany
EU-GMP Facility/Distribution

Leading wholesale pharmaceutical business in 28 countries, medical cannabis licenses.

USA
Headquarters & Distribution

CPG player with CBD gummies, vape products, and accessories with a customer base of over 250,000 people.

Portugal
Strategic Investment

Hoshi International project for EU-GMP facility and cannabis supply.

Australia
E-commerce engine

Wholesale distribution of consumer and medical vaporizers.

- Well-positioned to enter **THC market** when regulations permit
- Access to all **50 states** with **20,000+** points of distribution
- **Online B2C** represents close to half of US operations
- **400 SKUs** across the US operations
- JustCBD and Vessel achieved **gross margins** of **34%** and **53%**, respectively in Q2 2024



Melo Beverages



JustCBD Gummies



CBD + THC All in One



JustCBD Pet Treats



Haze Edibles and Vapes



Craftsman



Compass Rise



Helix Pipe



Core



JustCBD Sleep Gummies



Size of global cannabis market. Source: Prohibition Partners



- On April 1, 2024, **Germany legalized recreational cannabis** with explosive growth.
- With approximately 230,000 medical cannabis patients prior to legalization, **Germany continues to lead** the way in European medical cannabis; only represents 0.28% of the population. Other countries, such as Australia, have up to 2.3% of population (1.7 million patients) as medical cannabis patients.
- More than **40 countries have legalized** cannabis fully or partially for medical and/or adult use, with the total global market over **\$100 billion**, which Germany representing 10% of the total global market.
- Germany is the gateway to the European Union with the total market potential after legalization projected reach **100 million** cannabis consumers, which is larger than the U.S.

Flora is Undervalued Compared to Peer Group

	2024				2022				2019
(USD\$ MILLIONS)	Market Cap	TEV	TEV/Revenue	TEV/EBITDA	Market Cap	TEV	TEV/Revenue	TEV/EBITDA	Market Cap
	1,425	1,551	2.0x	21.8x	3,110	3,558	6.2x	69.6x	41,160
	458	770	3.7x	NM	2,669	2,878	6.9x	NM	10,485
	827	20	NM	0.5x	1,315	397	3.0x	NM	5,632
	330	320	1.6x	26.2x	771	830	4.7x	NM	15,934
	192	170	1.5x	0.7x	471	353	3.4x	NM	10,814
	562	523	0.8x	NM	1,120	1,080	21.1x	NM	11,940
	2,437	2,842	2.5x	8.3x	3,323	3,711	3.9x	12.3x	3,560
	2,314	3,291	2.4x	13.1x	4,210	5,187	4.2x	27.9x	7,099
Average	1,068	1,186	2.0x	11.8x	2,123	2,249	6.7x	36.6x	13,328
	14	13	0.2x	NM	78	78	6.0x	NM	NM

1

Premier small-cap opportunity on the **NASDAQ**. A potent blend of **growth and stability** in the cannabis market.

2

Aggressive M&A and strategic expansion. A bold approach pushing reach into lucrative markets like Germany, and the United States. Diversified revenue streams and positions well in regions with rapidly evolving cannabis regulations.

3

Diverse product portfolio appealing to wide, growing consumer base, from wellness essentials like JustCBD to premium cannabis accessories under the Vessel Brand.

4

Clean balance sheet provides liquidity and positions the company to capitalize on market opportunities. **No long-term debt**. Operations have been optimized with meaningful reductions in operating expenses and cash used in operating activities.

5

Favorable political timing with a solid footprint in Germany, which is the largest legal cannabis market in the West. In the US, support for legalization has reached 70% in 2023 with both Presidential candidates signaling support for cannabis reform.

6

Global reach and market penetration with international presence in key cannabis markets, from the U.S. to Europe.

7

Leadership and proven success with a strong vision for the business, plenty of skin in the game. A team of seasoned executives in cannabis, finance, and global capital markets.



THANK YOU

FOR MORE INFORMATION: CLIFFORD.STARKE@FLORAGROWTH.COM +1 954 701 5612